Tα1 has also demonstrated inhibitory effects on tumor metastasis and invasion by blocking STAT3-MMP2 signaling in NSCLC cells with high PD-L1 expression, suggesting a potential benefit of Tα1 combined with PD-1/PD-L1 ICIs for patients with PD-L1-positive NSCLC99. This evidence concerns the gene CD274 and non-small cell lung carcinoma.